---
layout: default
title: Ribociclib
parent: Model Prediction Only (L5)
nav_order: 730
evidence_level: L5
indication_count: 4
---

# Ribociclib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **4** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Ribociclib: From HR+/HER2- Breast Cancer to Myeloid Leukemia

## One-Sentence Summary

> Ribociclib is a CDK4/6 inhibitor originally developed and marketed globally for hormone receptor-positive, HER2-negative advanced breast cancer, though it is not currently registered in India.
> The TxGNN model's top prediction suggests possible relevance to **Myeloid Leukemia**,
> but this is currently supported only by **0 clinical trials** and **3 publications**, one of which actually describes AML as a treatment-related adverse event rather than a therapeutic benefit.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in India regulatory data (drug not marketed); globally approved for HR+/HER2- advanced breast cancer as a CDK4/6 inhibitor |
| Predicted New Indication | Myeloid Leukemia |
| TxGNN Prediction Score | 99.35% |
| Evidence Level | L4 (preclinical/mechanistic study only; no clinical trials) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for ribociclib is not available in this evidence pack. Based on known information, ribociclib is an oral, highly selective CDK4/6 (cyclin-dependent kinase 4/6) inhibitor; its efficacy in HR+/HER2- metastatic breast cancer has been established through multiple Phase 3 trials, and mechanistically it may be applicable to other proliferative malignancies where the cyclin D–CDK4/6–Rb pathway drives tumor growth.

One preclinical study in the evidence pack (PMID 32560251) explored CDK4/6 inhibitors as a strategy to overcome ABCB1/ABCG2-mediated drug resistance in acute myeloid leukemia (AML) cell lines — providing a plausible, though early-stage, mechanistic rationale for the TxGNN prediction.

However, a second publication in the same evidence set (PMID 30575100) reports a case of **AML arising as a complication after CDK4/6 inhibitor treatment**, in a patient with underlying clonal hematopoiesis. This is an important countervailing signal: it suggests CDK4/6 inhibition may, in some contexts, be associated with AML as an adverse event rather than as a therapeutic target. The third literature item retrieved (PMID 41641105, a vulvar/breast adenocarcinoma case report) does not appear directly relevant to AML and is likely a low-relevance match. Given this mixed and very limited evidence base, the mechanistic plausibility should be treated as hypothesis-generating only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Myeloid Leukemia.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [32560251](https://pubmed.ncbi.nlm.nih.gov/32560251/) | 2020 | Preclinical/Mechanistic | Cancers | CDK4/6 inhibitors evaluated in vitro for overcoming ABCB1/ABCG2-mediated drug resistance in AML cells — supportive but early-stage rationale |
| [30575100](https://pubmed.ncbi.nlm.nih.gov/30575100/) | 2019 | Case Report (adverse event) | American Journal of Hematology | AML with eosinophilia occurring **after** CDK4/6 inhibitor treatment, linked to underlying clonal hematopoiesis — signals possible risk, not benefit |
| [41641105](https://pubmed.ncbi.nlm.nih.gov/41641105/) | 2026 | Case Report (low relevance) | Frontiers in Oncology | Describes concurrent vulvar and breast adenocarcinoma; does not directly address ribociclib or myeloid leukemia |

---

## India Market Information

Ribociclib currently has **0 registered licenses** in India (market status: Not Marketed). No authorization, product, or approved-indication data is available for this market.

---

## Cytotoxicity (Antineoplastic Drug)

Ribociclib is an antineoplastic agent (oral CDK4/6 inhibitor used in breast cancer treatment), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) |
| Myelosuppression Risk | High — literature evidence consistently documents neutropenia, leukopenia, and thrombocytopenia as the most common hematologic toxicities of CDK4/6 inhibitors, including ribociclib |
| Emetogenicity Classification | Low to moderate (typical for oral targeted kinase inhibitors) |
| Monitoring Items | Complete blood count (CBC) with differential, liver function tests, and ECG/QT interval monitoring (hepatic toxicity and QT prolongation reported in class literature) |
| Handling Protection | Not a conventional cytotoxic agent, but should be handled per institutional hazardous oral oncolytic protocols given mutagenic/teratogenic potential |

---

## Safety Considerations

- **Drug Interactions**: Ribociclib has a large documented interaction profile (579 total interactions in this dataset). Notable **Major**-level interactions include **Clarithromycin** and **Dolasetron**. Numerous **Moderate**-level interactions were also identified, including with Metformin, Pioglitazone, Famotidine, Cimetidine, Dexamethasone, and several corticosteroids/laxatives/antiemetics — consistent with ribociclib's known CYP3A4-mediated and QT-related interaction risk.

No verified key warnings or contraindications data was available in this evidence pack (source data gap); please refer to the package insert for complete safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Myeloid Leukemia prediction is supported only by one early-stage preclinical study and lacks any clinical trial evidence; a second, directly relevant publication actually reports AML as a possible adverse consequence of CDK4/6 inhibitor therapy rather than a therapeutic benefit. This conflicting signal, combined with the complete absence of clinical trial data, means the evidence does not currently support advancing this indication.

**To proceed, the following is needed:**
- Resolve the conflicting preclinical vs. adverse-event signal for AML before any further investment (e.g., mechanistic follow-up studies distinguishing therapeutic effect from treatment-emergent hematologic malignancy)
- Obtain ribociclib's original mechanism of action (MOA) and TFDA/regulatory warning/contraindication data (currently flagged as blocking data gaps, DG001/DG002)
- Note: within this same evidence pack, the **Thrombocytopenia** prediction (rank 2, score 99.27%) is supported by substantially stronger evidence — 5 clinical trials and ~20 publications — and may warrant separate, prioritized evaluation
- If pursuing the AML hypothesis further, require at least one completed Phase 1/2 trial specifically evaluating ribociclib in AML before upgrading the evidence level
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

